Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road
China Brands

India's Wockhardt partners with Chinese company to develop novel antibiotic Nafithromycin

August 30, 2021


Abstract : India's Wockhardt has partnered with China's Jiangxi Jemincare Group Company to develop and commercialize novel broad-spectrum antibiotic Nafithromycin, the Indian company said in its filing with the Bombay Stock Exchange on Thursday.

MUMBAI, Aug. 26 (Xinhua) -- India's Wockhardt has partnered with China's Jiangxi Jemincare Group Company to develop and commercialize novel broad-spectrum antibiotic Nafithromycin, the Indian company said in its filing with the Bombay Stock Exchange on Thursday.

Wockhardt has completed global clinical Phase I and II studies with Nafithromycin, which belongs to the lactone/ketolide class for respiratory tract infections.

The antibiotic is active against entire range of bacterial pathogens associated with community-acquired bacterial pneumonia including macrolide resistance strains which is around 80 percent in China and several other Asian countries.

As per the pact, the Chinese company will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets. Wockhardt will receive an upfront payment and will be eligible for regulatory-linked milestone payments.

Wockhardt would supply the product to the Chinese company and will receive royalties on net sales and would transfer the manufacturing technology at mutually agreed time, the statement said.

"Bacterial pneumonia and other respiratory tract infections trigger the highest volume of antibiotic prescriptions world over. Prevalence of antimicrobial resistance poses a therapeutic challenge to physicians with extremely limited safer and effective therapeutic options, particularly for most vulnerable group such as pediatric and older age group patients," said Mahesh Patel, chief scientific officer of Wockhardt. Enditem

Scan the QR code and push it to your mobile phone

Keyword: Jemincare

Reading:

Jemincare

Jemincare

Jemincare selected into Xinhua's National Brands Project

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial